SFTPA2 and cancer: We identified four proteins that were both associated with the risk of cancer in the main analyses and had directionally concordant, conventionally significant support from all three additional analyses, i.e., long (> 7 years) time-to-diagnosis, cis-pQTL, and exGS analyses: SFTPA2 for lung cancer [1.24 (1.14–1.35)], TNFRSF1B [1.28 (1.19–1.37)] and CD74 [1.68 (1.49–1.90)] for NHL and ADAM8 for leukaemia [1.87 (1.69–2.06)] (Fig. 5).